Advertisement

Breast: Ductal Carcinoma In Situ (DCIS)

Chapter

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a proliferation of malignant epithelial cells within parenchymal structures of the breast, which is distinguished from invasive carcinoma by the absence of stromal invasion through the limiting basement membrane. Although the incidence of DCIS has apparently increased over the last 20 years, this is interpreted as a result of the enhanced detection through mammographic breast screening programmes rather than a true increase in frequency of the disease. However, despite the increased numbers of radiologically identified and surgically excised cases, less is understood about the biological and clinical aspects of DCIS than invasive breast cancer. Indeed, research into all aspects, including risk factors, genetics, biology, biomarkers, prognostic factors and the clinical management, of DCIS all lapse behind the significant translational knowledge gained into invasive breast cancer in the last decade.

Keywords

Invasive Breast Cancer Invasive Carcinoma Atypical Ductal Hyperplasia Flat Epithelial Atypia Architectural Growth Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55:2698–2708, which is greater in pre-menopausal women (approaching a sixfold risk)PubMedCrossRefGoogle Scholar
  2. 2.
    London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–944PubMedCrossRefGoogle Scholar
  3. 3.
    Stomper PC, Cholewinski SP, Penetrante RB, Harlos JP, Tsangaris TN (1993) Atypical hyperplasia: frequency and mammographic and pathologic relationships in excisional biopsies guided with mammography and clinical examination. Radiology 189:667–671PubMedGoogle Scholar
  4. 4.
    Tavassoli FA, Norris HJ (1990) A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intra-ductal hyperplasia of the breast. Cancer 65:518–529PubMedCrossRefGoogle Scholar
  5. 5.
    Gillett CE, Lee AHS, Millis RR, Barnes DM (1998) Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 184:396–400PubMedCrossRefGoogle Scholar
  6. 6.
    Otterbach F, Bànkfalvi A, Bergner S, Decker T, Krech R, Boecker W (2000) Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 37:232–240PubMedCrossRefGoogle Scholar
  7. 7.
    Lakhani SR, Collins N, Stratton MR, Sloane JP (1995) Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48:611–615PubMedCrossRefGoogle Scholar
  8. 8.
    Emery LA, Tripathi A, King C (2009) Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 175:1292–1302PubMedCrossRefGoogle Scholar
  9. 9.
    Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRefGoogle Scholar
  10. 10.
    Geschickter CF, Lewis D (1938) Comedo carcinomas of the breast. Arch Surg 33:225–244Google Scholar
  11. 11.
    Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: Follow up after biopsy alone. Cancer 49:751–758PubMedCrossRefGoogle Scholar
  12. 12.
    Rosen PP, Braun DW Jr, Kinne DW (1980) The clinical significance of preinvasive breast carcinoma. Cancer 46:919–925PubMedCrossRefGoogle Scholar
  13. 13.
    Betsill WLJ, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239:1863–1867PubMedCrossRefGoogle Scholar
  14. 14.
    Lampejo OT, Barnes DM, Smith P, Millis RR (1994) Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 11:215–222PubMedGoogle Scholar
  15. 15.
    Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE (1997) The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer 80:1740–1745PubMedCrossRefGoogle Scholar
  16. 16.
    Millis RR, Barnes DM, Lampejo OT, Egan MK, Smith P (1998) Tumour grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRefGoogle Scholar
  17. 17.
    Buerger H, Otterbach F, Simon R et al (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189: 521–526PubMedCrossRefGoogle Scholar
  18. 18.
    Boecker W, Buerger H, Schmitz K et al (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195:415–421PubMedCrossRefGoogle Scholar
  19. 19.
    Andersson I, Aspegren K, Janzon L et al (1988) Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. Br Med J 297:943–948CrossRefGoogle Scholar
  20. 20.
    Anderson TJ, Lamb J, Donnan P et al (1991) Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 64:108–113PubMedCrossRefGoogle Scholar
  21. 21.
    Gibbs NM (1985) Comparative study of the histopathology of breast cancer in a screened and unscreened population investigated by mammography. Histopathology 9:1307–1318PubMedCrossRefGoogle Scholar
  22. 22.
    Haagensen CD (1986) Diseases of the breast. WB Saunders, PhiladelphiaGoogle Scholar
  23. 23.
    Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH (1990) Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335:519–522PubMedCrossRefGoogle Scholar
  24. 24.
    Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11:193–198PubMedGoogle Scholar
  25. 25.
    Meijnen P, Gilhuijs KG, Rutgers EJ (2008) The effect of margins on the clinical management of ductal carcinoma in situ of the breast. J Surg Oncol 98:579–584PubMedCrossRefGoogle Scholar
  26. 26.
    MacDonald HR, Silverstein MJ, Mabry H et al (2005) Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 190: 521–525PubMedCrossRefGoogle Scholar
  27. 27.
    Waldman FM, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Ljung BM (2000) Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 92:313–320PubMedCrossRefGoogle Scholar
  28. 28.
    Sakorafas GH, Farley DR (2003) Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12:221–240PubMedCrossRefGoogle Scholar
  29. 29.
    Holland R, Hendriks JH (1994) Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol 11:181–192PubMedGoogle Scholar
  30. 30.
    Lester SC, Bose S, Chen Y-Y et al (2009) Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15–25PubMedGoogle Scholar
  31. 31.
    Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ (1993) Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 24:16–23PubMedCrossRefGoogle Scholar
  32. 32.
    Quinn CM, Ostrowski JL (1997) Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast. J Clin Pathol 50:596–599PubMedCrossRefGoogle Scholar
  33. 33.
    Hittmair A, Lininger RA, Tavassoli FA (1998) Ductal carcinoma in situ (DCIS) in the male breast. Cancer 83:2139–2149PubMedCrossRefGoogle Scholar
  34. 34.
    Ellis IO, Coleman D, Wells C et al (2006) Impact of a National External Quality Assurance Scheme for breast pathology in the United Kingdom. J Clin Pathol 59:138–145PubMedCrossRefGoogle Scholar
  35. 35.
    Badve S, A’Hern RP, Ward AM et al (1998) Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Hum Pathol 29:915–923PubMedCrossRefGoogle Scholar
  36. 36.
    Silverstein MJ, Poller DN, Waisman JR et al (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154–1157PubMedCrossRefGoogle Scholar
  37. 37.
    Poller DN, Silverstein MJ, Galea M et al (1994) Ductal carcinoma in situ of the breast. A proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 7:257–262PubMedGoogle Scholar
  38. 38.
    Silverstein MJ, Lagios MD, Craig PH et al (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267–2274PubMedCrossRefGoogle Scholar
  39. 39.
    O’Malley FP, Bane A (2008) An update on apocrine lesions of the breast. Histopathology 52:3–10PubMedCrossRefGoogle Scholar
  40. 40.
    EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL et al. (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387.Google Scholar
  41. 41.
    UK Coordinating Committee on Cancer Research Ductal Carcinoma In Situ Working Party (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102CrossRefGoogle Scholar
  42. 42.
    Di Saverio S, Catena F, Santini D et al (2008) 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 109:405–416PubMedCrossRefGoogle Scholar
  43. 43.
    Vargas C, Kestin L, Go N et al (2005) Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 63:1514–1521PubMedCrossRefGoogle Scholar
  44. 44.
    Ringberg A, Nordgren H, Thorstensson S et al (2007) Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast – results from the Swedish randomised trial. Eur J Cancer 43:291–298PubMedCrossRefGoogle Scholar
  45. 45.
    Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86:429–438PubMedCrossRefGoogle Scholar
  46. 46.
    Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R (2005) Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. Breast J 11:242–247PubMedCrossRefGoogle Scholar
  47. 47.
    Bagnall MJ, Evans AJ, Wilson AR et al (2001) Predicting invasion in mammographically detected microcalcification. Clin Radiol 56:828–832PubMedCrossRefGoogle Scholar
  48. 48.
    Bobrow LG, Happerfield LC, Gregory WM et al (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199–207PubMedGoogle Scholar
  49. 49.
    Poller DN, Roberts EC, Bell JA et al (1993) p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24:463–468PubMedCrossRefGoogle Scholar
  50. 50.
    Poller DN, Snead DR, Roberts EC et al (1993) Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 68:156–161PubMedCrossRefGoogle Scholar
  51. 51.
    Roylance R, Gorman P, Hanby A, Tomlinson I (2002) Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32–36PubMedCrossRefGoogle Scholar
  52. 52.
    Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO (2008) Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 32:513–523PubMedCrossRefGoogle Scholar
  53. 53.
    Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedCrossRefGoogle Scholar
  54. 54.
    Buerger H, Otterbach F, Simon R et al (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189:521–526PubMedCrossRefGoogle Scholar
  55. 55.
    Boecker W, Buerger H, Schmitz K et al (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195:415–421PubMedCrossRefGoogle Scholar
  56. 56.
    Vincent-Salomon A, Lucchesi C, Gruel N et al (2008) Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 14:1956–1965Google Scholar
  57. 57.
    Bijker N, Peterse JL, Duchateau L et al (2001) Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539–544PubMedCrossRefGoogle Scholar
  58. 58.
    Meeker AK, Hicks JL, Gabrielson E et al (2004) Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 164: 925–935PubMedCrossRefGoogle Scholar
  59. 59.
    Mommers EC, Leonhart AM, Falix F et al (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194:327–333PubMedCrossRefGoogle Scholar
  60. 60.
    Ottesen GL (2003) Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS 108:1–67Google Scholar
  61. 61.
    Shackney SE, Silverman JF (2003) Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 10:278–290PubMedCrossRefGoogle Scholar
  62. 62.
    Cornfield DB, Palazzo JP, Schwartz GF et al (2004) The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 100:2317–2327PubMedCrossRefGoogle Scholar
  63. 63.
    Castro NP, Osório CABT, Torres C et al (2008) Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10:R87PubMedCrossRefGoogle Scholar
  64. 64.
    Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRefGoogle Scholar
  65. 65.
    Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCrossRefGoogle Scholar
  66. 66.
    Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRefGoogle Scholar
  67. 67.
    Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67PubMedCrossRefGoogle Scholar
  68. 68.
    Livasy CA, Perou CM, Karaca G et al (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38:197–204PubMedCrossRefGoogle Scholar
  69. 69.
    Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRefGoogle Scholar
  70. 70.
    Thompson A, Brennan K, Cox A et al (2008) Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res 10:R26PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Cancer StudiesKing’s College LondonLondonUK

Personalised recommendations